FRE.HM - FRESENIUS SE+CO.KGAA O.N.

Hamburg - Hamburg Delayed Price. Currency in EUR
67.28
+0.12 (+0.18%)
As of 1:45PM CET. Market open.
Stock chart is not supported by your current browser
Previous Close67.16
Open67.20
Bid67.28 x 0
Ask67.30 x 0
Day's Range67.20 - 67.30
52 Week Range60.35 - 79.75
Volume196
Avg. Volume742
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters15 days ago

    Fresenius CFO backs acquisition course - Boersen-Zeitung

    FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief ...

  • Reuters15 days ago

    Fresenius CFO backs acquisition course -Boersen-Zeitung

    German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying. Last year Fresenius ...

  • Drugmaker Warned Again for Ignoring Bad Quality Tests
    Bloomberg20 days ago

    Drugmaker Warned Again for Ignoring Bad Quality Tests

    U.S. regulators warned Fresenius SE last month that workers in one of its cancer-drug plants ignored tests that found the products made there weren’t meeting sterility standards.

  • Drugmaker Ignored More Than 200 Bad Quality Tests, FDA Says
    Bloomberg27 days ago

    Drugmaker Ignored More Than 200 Bad Quality Tests, FDA Says

    U.S. regulators warned Fresenius SE after the company’s Indian plant that makes cancer-drug ingredients for the U.S. market aborted hundreds of drug-quality tests because they seemed like they were going ...

  • Reuterslast month

    Fresenius now sees completion of Akorn takeover in early 2018

    Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday. "While we've been focused on a 2017 close, it's now clear that closing in early 2018 is more likely, and we're quite comfortable with this timeline," the spokesman said.

  • Reuters2 months ago

    Fresenius says Akorn deal closure could take until next year

    German healthcare group Fresenius SE (FREG.DE) said the planned takeover of Akorn (AKRX.O), a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected. Akorn's business has deteriorated since Fresenius struck the acquisition agreement in April, valuing the maker of medical creams, ophthalmic drugs and oral liquids at $4.75 billion (3.6 billion pounds). Akorn's operating income has slumped on supply disruptions and competition for a range of drugs.

  • Reuters3 months ago

    Fresenius says Akorn troubles could continue into next year

    German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term. The 2018 targets for Akorn, which Fresenius plans to take over at the end of this year, were "challenging", the diversified drugmaker said in presentation slides posted on its website after the release of its quarterly results.

  • Reuters3 months ago

    Fresenius adj EBIT up 11 pct on hospitals, drugs

    German healthcare group Fresenius said third-quarter adjusted net income gained 11 percent on higher drug sales and helped by the addition of Spanish hospitals chain Quironsalud. Quarterly net income adjusted ...

  • Reuters3 months ago

    Billionaire Insys founder charged in U.S. opioid bribe case

    The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys' majority shareholder who stepped down as chief executive in January, was charged with engaging in conspiracies to commit racketeering, mail fraud and wire fraud in an indictment filed in federal court in Boston. Following a court hearing in Phoenix, Kapoor, 74, was released on a $1 million bond.

  • Reuters4 months ago

    Senvest Management shorting drug stocks Insys, Akorn, Fresenius

    New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, Speaking at the Sohn Conference ...

  • Fresenius Pays an Arm, and Maybe a Leg
    Bloomberg6 months ago

    Fresenius Pays an Arm, and Maybe a Leg

    The medical-devices maker can't afford to get sucked into an auction.

  • Associated Press6 months ago

    Fresenius posts 2Q profit

    The Bad Homburg, Germany-based company said it had profit of 48 cents per share. The dialysis services provider posted revenue of $4.92 billion in the period. Fresenius shares have increased 12 percent ...

  • Nestle’s New CEO to Show Off M&A Acumen as Activists Circle
    Bloomberg7 months ago

    Nestle’s New CEO to Show Off M&A Acumen as Activists Circle

    Nestle SA Chief Executive Officer Mark Schneider previously transformed a sleepy German hospital operator into a stock-market darling via more than 30 acquisitions. Now he wants to return to dealmaking ...

  • Reuters7 months ago

    Loeb's Third Point targets 'staid' Nestle for change

    Activist investor Daniel Loeb's Third Point LLC on Sunday unveiled a more than 1 percent stake in Switzerland's Nestle SA and urged the world's largest packaged foods maker to improve its margins, buy back stock and shed non-core businesses. Third Point disclosed its Nestle position in a letter to investors, in which it argued the food company should sell its 23 percent stake in French cosmetics firm L'Oreal SA. "We feel strongly that in order to succeed, Dr. Schneider will need to articulate a decisive and bold action plan that addresses the staid culture and tendency towards incrementalism that has typified the company’s prior leadership and resulted in its long-term underperformance," Third Point wrote in the letter.

  • Reuters9 months ago

    European shares slip from 20-month highs, Apple suppliers slip

    European shares slipped slightly from the 20-month highs they hit in the previous session, as investors locked in some profits following some underwhelming company results. Shares in several Apple suppliers fell after the smartphone giant reported a surprise dip in sales of its flagship iPhone. Dialog Semiconductor shares slid 2.9 percent at the open.

  • Fresenius Tops Estimates, Raises Outlook
    Bloomberg9 months ago

    Fresenius Tops Estimates, Raises Outlook

    Fresenius CEO Stephan Sturm discusses the company's earnings and performance. He speaks on "Bloomberg Markets." (Source: Bloomberg)

  • TheStreet.com9 months ago

    Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

    Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

  • Fresenius Spends Billions On a Falling Akorn
    Bloomberg9 months ago

    Fresenius Spends Billions On a Falling Akorn

    Stephan Sturm can't resist a deal.

  • TheStreet.com9 months ago

    Fresenius and Merck Stocks Top DAX on Biosimilars Deal

    Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.

  • Reuters9 months ago

    Fresenius picks up M&A pace with Akorn, Merck KGaA deals

    German healthcare group Fresenius SE & Co KGaA (FREG.DE) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (AKRX.O) for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA. Takeovers were part of Fresenius's growth strategy under previous boss Ulf Mark Schneider, now leading Nestle (NESN.S). The latest deals are in keeping with Fresenius's focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube feeding and blood transfusion equipment.

  • Bloomberg9 months ago

    Fresenius Buys Akorn for $4.3 Billion in U.S. Expansion

    In just 10 months at the head of Germany’s Fresenius SE, Chief Executive Officer Stephan Sturm has now inked the health-care provider’s two biggest-ever deals.